Results 31 to 40 of about 17,175,483 (375)

Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines

Amyloid: Journal of Protein Folding Disorders, 2021
AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was ...
V. Sanchorawala, M. Boccadoro, M. Gertz, U. Hegenbart, E. Kastritis, H. Landau, P. Mollee, A. Wechalekar, G. Palladini   +8 more
semanticscholar   +1 more source

Aggregation in AL Amyloidosis [PDF]

Biophysical Journal, 2014
Systemic light chain amyloidosis (AL amyloidosis) is a rare but fatal systemic amyloid disease. It usually strikes in the wake of myeloma, a form of cancer that affects plasma cells in the adaptive immune system. During plasma cell development from primary B cells, the immunoglobulin light chain (LC) genes undergo several rearrangements that leave each
Kathrin Andrich, Jan Bieschke
openaire   +2 more sources

Supportive Care in AL Amyloidosis [PDF]

Acta Haematologica, 2020
Immunoglobulin light-chain (AL) amyloidosis is a systemic disease characterized by the production and deposition of light chain-derived amyloid fibrils in different organs. Prompt treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response.
Joan Bladé, Natalia Tovar, José T. Ortiz-Pérez, M. Teresa Cibeira, Carlos Fernádez de Larrea, Luis F. Quintana   +5 more
openaire   +3 more sources

Phase 1a/b Study of Monoclonal Antibody CAEL-101 (11-1F4) in Patients with AL Amyloidosis.

Blood, 2021
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by pathologic deposition of immunoglobulin light chains as amyloid fibrils in vital organs, leading to organ impairment and eventual death. That the process is reversible was evidenced
C. Edwards, N. Rao, D. Bhutani, M. Mapara, J. Radhakrishnan, Sofia Shames, M. Maurer, Siyang Leng, A. Solomon, S. Lentzsch, A. Eisenberger   +10 more
semanticscholar   +1 more source

Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

Swiss Medical Weekly, 2020
Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into insoluble beta-sheet rich structures that deposit extracellularly in different organs, eventually compromising their function.
Rahel Schwotzer, Andreas J. Flammer, Sabine Gerull, Thomas Pabst, Paolo Arosio, Manuela Averaimo, Ulrike Bacher, Peter Bode, Andrea Cavalli, Adalgisa Condoluci, Stefan Dirnhofer, Nadia Djerbi, Stephan W. Dobner, Thomas Fehr, Maura Garofalo, Ariana Gaspert, Raphael Heimgartner, Annemarie Hübers, Hans H. Jung, Chiara Kessler, Raphael Knöpfel, Natallia Laptseva, Robert Manka, Luca Mazzucchelli, Martin Meyer, Violeta Mihaylova, Pierre Monney, Alessio Mylonas, René Nkoulou, Aju P. Pazhenkottil, Otmar Pfister, Axel Rüfer, Adrian Schmidt, Harald Seeger, Simon F. Stämpfli, Guido Stirnimann, Thomas Suter, Marie Théaudin, Giorgio Treglia, Alexandar Tzankov, Friederike Vetter, Markus Zweier, Bernhard Gerber   +42 more
doaj   +1 more source

Difficulties in diagnosis of primary AL-amyloidosis

Онкогематология, 2021
Objective of the study: analysis of AL-amyloidosis (AL-A) diagnostics in real clinical practice and to determine the main approaches for the earlier detection of this disease.Materials and methods.
V. A. Khyshova, I. G. Rekhtina, M. V. Firsova, L. P. Mendeleeva   +3 more
doaj   +1 more source

Systemic amyloidosis in England: an epidemiological study. [PDF]

, 2013
Epidemiological studies of systemic amyloidosis are scarce and the burden of disease in England has not previously been estimated. In 1999, the National Health Service commissioned the National Amyloidosis Centre (NAC) to provide a national clinical ...
Banypersad, SM, Dungu, J, Gibbs, SD, Gillmore, JD, Hawkins, PN, Lachmann, HJ, Pinney, JH, Smith, CJ, Taube, JB, Venner, CP, Wechalekar, AD, Whelan, CJ   +11 more
core   +1 more source

Comprehensive Review of AL amyloidosis: some practical recommendations

Blood Cancer Journal, 2021
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains (FLC)
Rama Al Hamed, A. Bazarbachi, A. Bazarbachi, F. Malard, J. Harousseau, M. Mohty   +5 more
semanticscholar   +1 more source

Incidence and survival in non-hereditary amyloidosis in Sweden [PDF]

, 2012
BACKGROUND: Amyloidosis is a heterogeneous disease caused by deposition of amyloid fibrils in organs and thereby interfering with physiological functions.
Asta Försti, Jan Sundquist, Kari Hemminki, Kristina Sundquist, Xinjun Li   +4 more
core   +1 more source

Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA.

Blood, 2020
Although no therapies are currently approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered a standard treatment for newly diagnosed patients.
G. Palladini, E. Kastritis, M. Maurer, J. Zonder, M. Minnema, A. Wechalekar, A. Jaccard, Hans C. Lee, N. Bumma, J. Kaufman, E. Medvedova, T. Kovacsovics, M. Rosenzweig, V. Sanchorawala, X. Qin, S. Vasey, B. Weiss, J. Vermeulen, G. Merlini, R. Comenzo   +19 more
semanticscholar   +1 more source